Lilly's Competitive Clinical Research Grant
Lilly’s grant program funds investigator-led clinical research in dermatology and gastroenterology, focusing on studies of lebrikizumab and mirkizumab in key patient populations.
Funder: Eli Lilly and Company
Due Dates (Anticipated): February 2027: Full application deadline for RFP: Efficacy of Lebrikizumab in patients with fibrosing skin conditions (projected) | February 2027: Full application deadline for RFP: How does lebrikizumab impact post-inflammatory dyspigmentation as measured by the PDCA-Derm™ scale in patients with moderate to severe atopic dermatitis? (projected) | June 2027: Full application deadline for RFP in Canada: Real-world effectiveness of mirkizumab in IBD and disease-state epidemiology in overweight and/or obese individuals living with IBD in Canada (projected)
Funding Amounts: Funding varies by proposal and scope; budget limits and drug support are specified in individual RFPs.
Summary: Supports investigator-initiated clinical research addressing targeted Lilly therapeutic priorities, with applicant-led study design and execution.
Key Information: All dates are anticipated/projected; confirm on the program site before applying.
Description
Lilly's Competitive Clinical Research Grant program invites external researchers to submit proposals for studies that are initiated, designed, and sponsored by the applicants themselves. The program issues public Requests for Proposals (RFPs) outlining specific research areas of interest and expected review timelines. Proposals are evaluated by global committees of Lilly medical and scientific staff, and may also undergo review by external experts. Approved research projects are managed and regulated by the grantee, ensuring full investigator responsibility for study design, conduct, and regulatory oversight. The program is intended to advance clinical research in targeted therapeutic areas aligned with Lilly's current priorities, such as dermatology and gastroenterology.
